Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension

Respiration

Volumn 91, Issue 4, 2016, Pages 307-315

  Gabriel, Laurence ^a   Delavenne, Xavier ^a,b   Bedouch, Pierrick ^c   Khouatra, Chahéra ^d   Bouvaist, Hélène ^e   Cordier, Jean François ^f   Mornex, Jean François ^f   Pison, Christophe ^c,e,g,h   Cottin, Vincent ^f   Bertoletti, Laurent ^a,b,g  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIV GRENOBLE ALPES   (France)

^d Centre de Compétences de l'Hypertension Artérielle Pulmonaire   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g INSERM   (France)

^h European Institute for Systems Biology and Medicine   (France)

Author keywords

Anticoagulant; Atrial fibrillation; Direct oral anticoagulant; Pulmonary arterial hypertension; Pulmonary hypertension; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; ANTIVITAMIN K; ATORVASTATIN; BOSENTAN; DABIGATRAN; ESOMEPRAZOLE; FUROSEMIDE; LEVOTHYROXINE; PANTOPRAZOLE; PARACETAMOL; POTASSIUM; RIVAROXABAN; SPIRONOLACTONE; TRAMADOL; CREATININE; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CHRONIC RESPIRATORY TRACT DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMORBIDITY; DRUG ACCUMULATION; DRUG INTERACTION; FEMALE; HEART CATHETERIZATION; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; THERAPEUTIC INDEX; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; HYPERTENSION, PULMONARY; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CREATININE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN K;

EID: 84973497853     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000445122     Document Type: Article

References (45)

1. Simonneau G, Gatzoulis M, Adatia I, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 suppl):D34-D41.
2. Tuder RM, Archer SL, Dorfmüller P, et al: Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 suppl):D4-D12.
3. Herve P, Humbert M, Sitbon O, et al: Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-458.
4. Humbert M, Sitbon O, Chaouat A, et al: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
5. Caldeira D, Loureiro MJ, Costa J, Pinto FJ, Ferreira JJ: Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. Can J Cardiol 2014; 30: 879-887.
6. Olsson KM, Delcroix M, Ghofrani HA, et al: Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57-65.
7. Galiè N, Humbert M, Vachiery J-L, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015; 46:ehv317.
8. Bertoletti L, Delavenne X, Montani D: Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents! Eur Respir J 2013; 41: 775-777.
9. BAATAF Investigators: The effect of lowdose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-1511.
10. Verstuyft C, Delavenne X, Rousseau A, et al: A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet 2012; 51: 41-53.
11. Schulman S, Kearon C, Kakkar AK, et al: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
13. Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
14. Büller HR, Prins MH, Lensin AWA, et al: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
15. Connolly SJ, Eikelboom J, Joyner C, et al: Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
16. Agnelli G, Büller HR, Cohen A, et al: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
17. Giugliano RP, Ruff CT, Braunwald E, et al: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
18. Büller HR, Décousus H, Grosso MA, et al: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
19. Castellucci LA, Cameron C, Le Gal G, et al: Clinical and safety outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis. JAMA 2014; 312: 1122-1135.
20. Delavenne X, Ollier E, Basset T, et al: A semimechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76: 107-113.
21. Lega J-C, Bertoletti L, Gremillet C, Boissier C, Mismetti P, Laporte S: Consistency of safety profile of new oral anticoagulants in patients with renal failure. J Thromb Haemost 2014; 12: 337-343.
22. Ruff CT, Giugliano RP, Braunwald E, et al: Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 6736: 1-8.
23. Hurdman J, Condliffe R, Elliot CA, et al: ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945-955.
24. Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A: Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J DOI: 10.1183/09031936.00039212.
25. van Giersbergen PLM, Halabi A, Dingemanse J: Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53: 589-595.
26. ANSM: Thesaurus des interactions médicamenteuses. Saint Denis, ANSM, 2013.
27. Preissner S, Kroll K, Dunkel M, et al: Super-CYP: A comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010; 38(database issue):D237-D243.
28. Drug Bank: Open Data Drug and Drug Target Database. www.drugbank.ca.
29. Weizmann Institute of Science: Gene Cards ® : The Human Gene Database. Rehovot, Weizmann Institute of Science.
30. US Food and Drug Administration: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Silver Spring, US Food and Drug Administration, 2011.
31. R: The R Project for Statistical Computing. Vienna, R Foundation for Statistical Computing.
32. Calcaianu G, Canuet M, Schuller A, Enache I, Chaouat A, Kessler R: Pulmonary arterial hypertension-specific drug therapy in COPD patients with severe pulmonary hypertension and mild-to-moderate airflow limitation. Respiration DOI: 10.1159/000441304.
33. Adir Y, Humbert M, Sitbon O, et al: Outof-proportion pulmonary hypertension and heart failure with preserved ejection fraction. Respiration 2013; 85: 471-477.
34. Girard A, Jouneau S, Chabanne C, et al: Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. Respiration 2015; 90: 220-228.
35. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
36. Decousus H, Tapson VF, Bergmann J-F, et al: Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69-79.
37. Ruíz-Giménez N, Suárez C, González R, et al: Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
38. Apostolakis S, Lane DA, Guo Y, Büller H, Lip GYH: Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding riskprediction scores in patients with atrial fibrillation undergoing anticoagulation. J Am Coll Cardiol 2012; 60: 861-867.
39. Bertoletti L, Quenet S, Mismetti P, et al: Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012; 39: 862-868.
40. Bertoletti L, Mismetti P, Decousus H: Letter by Bertoletti et al. regarding article, 'Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)'. Circulation 2014; 130:e108.
41. Camm AJ, Lip GYH, De Caterina R, et al: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
42. Jungbauer L, Dobias C, Stöllberger C, Weidinger F: The frequency of prescription of Pglycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost 2010; 8: 2069-2070.
43. Englund G, Hallberg P, Artursson P, Michaëlsson K, Melhus H: Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2004; 2: 8.
44. Hansen ML, Sørensen R, Clausen MT, et al: Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
45. Heidbuchel H, Verhamme P, Alings M, et al: Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507.